Aspirin resistance: clinical and molecular genetic evaluation techniques

Cover Page


Cite item

Full Text

Abstract

The article discusses the issues related to the personalization of preventive measures for ischemic stroke, in particular those associated with resistance to one of the most common antiplatelet drugs, aspirin. A brief historical note on investigation of acetylsalicylic acid is provided. The paper addresses the issue of etiological factors and epidemiology of aspirin resistance. Ananalysis and comparison of various techniques for evaluation of this phenomenon are performed. Separately, a molecular genetic aspect of the pathology is considered. In conclusion, the recommendations for overcoming tolerance to aspirin therapy are provided.

About the authors

Marine M. Tanashyan

Research Center of Neurology

Email: rasckey@live.com
Russian Federation, Moscow

M. A. Domashenko

Research Center of Neurology

Email: rasckey@live.com
Russian Federation, Moscow

Anton A. Raskurazhev

Research Center of Neurology

Author for correspondence.
Email: rasckey@live.com
Russian Federation, Moscow

References

  1. Инсульт: диагностика, лечение, профилактика. Под ред. З.А. Суслиной, М.А. Пирадова. М., 2008.
  2. Ионова В.Г., Суслина З.А., Демина Е.Г. Способ исследования антиагрегационного действия препаратов с помощью определения агрегации тромбоцитов in vitro. Патент на изобретение № 2188419.
  3. Орлов С.В., Домашенко М.А., Костырева М.В., Танашян М.М. Гемореология и гемостаз у больных с ишемическими инсультами на фоне метаболического синдрома. Клинич. медицина 2007; 1:40–44.
  4. Пирадов М.А. Антиагрегантная терапия в профилактике повторных ишемических инсультов. Русский медицинский журнал 2003;11 (12): 696–698.
  5. Суслина З.А., Танашян М.М., Ионова В.Г. Ишемический инсульт: кровь, сосудистая стенка, антитромботическая терапия. М., Медицина, 2005.
  6. Суслина З.А. Ишемические нарушения мозгового кровообращения и система простаноидов (клинико-биохимическое исследование). Дис. докт. мед. наук. М., 1990, 339 с.
  7. Суслина З.А., Высоцкая В.Г. Антиагрегационное действие и клинический эффект малых доз аспирина при лечении больных с цереброваскулярной патологией на фоне артериальной гипертензии. Клинич. медицина 1983; 9: 51.
  8. Суслина З.А., Танашян М.М., Ионова В.Г. и др. Кавинтон в лечении больных с ишемическими нарушениями мозгового кровообращения – новые аспекты действия. Лечение нервных болезней 2002; 3(3): 19–24.
  9. Суслина З.А., Танашян М.М., Домашенко М.А. Антитромботическая терапия ишемических нарушений мозгового кровообращения с позиций доказательной медицины. М, 2009.
  10. Суслина З.А., Танашян М.М., Домашенко М.А. Проблема резистентности к антиагрегантным препаратам у пациентов с цереброваскулярными заболеваниями. Вестник Российской Академии медицинских наук 2011; 7: 3–8.
  11. Танашян М.М., Ионова В.Г., Орлов С.В. и др. Хронические цереброваскулярные заболевания, метаболический синдром и состояние систем гемореологии и гемостаза.Терапевтич. архив 2010;10: 19–24.
  12. Танашян М.М., Орлов С.В., Домашенко М.А., Ионова В.Г. Метаболический синдром и ишемический инсульт. Анн. клинич. и эксперим. неврол. 2007;1 (3): 5–11.
  13. Танашян М.М., Хамидова З.М., Ионова В.Г. и др. Способ выявления резистентности к антиагрегантным препаратам у больных с прогрессирующим церебральным атерослерозом. Патент на изобретение № 2012106483/15 (009859).
  14. Хамидова З.М. Цереброваскулярная патология: гемореологические и генетические факторы прогрессирования. Дисс. канд.мед. наук. М., 2013.
  15. Andrioli G. et al. Defective platelet response to arachidonic acid and thromboxane A2 in subjects with Pl (A2) polymorphism of beta(3)subunit (glycoprotein IlIa). Br. J. Haematol. 2000;110: 911–918.
  16. Angiolillo D.J. Antiplatelet therapy in type 2 diabetes mellitus. Curr.Opin Endocrinol Diabetes Obes 2007; 14: 124–131.
  17. Bousser M.G., Amarenco P., Chamorro A. et al. PERFORM Study Investigators Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial.Lancet 2011; 377 (9782): 2013–2022.
  18. Calkin A.C., Drew B.G., Ono A. et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009; 120 (21):2095–2104.
  19. Craven L.L. Prevention of coronary and cerebral thrombosis. Miss Valley Med J. 1956; 78 (5): 213–215.
  20. Davi G., Patrono C. Platelet activation and atherothrombosis. The New England Journal of Medicine 2007; 357 (24): 2482–2494.
  21. Eikelboom J.W. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction: stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105(14): 1650–1655.
  22. Eikelboom J.W. et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 2008; 118 (17): 1705–1712.
  23. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008; 25 (5):457–507.
  24. Fan L., Cao J., Liu L. et al. Frequency, risk factors, prognosis, and genetic polymorphism of the cyclooxygenase-1 gene for aspirin resistance in elderly Chinese patients with cardiovascular disease. Gerontology 2013; 59: 122–131.
  25. Friend M., Vucenik I., Miller M. Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 2003; 326 (7380): 82–83.
  26. Gorelick P.B. North american perspective of antiplatelet agents. In: Barnett HJM, Bogousslavsky J, Meldrum H, editors. Advances in Neurology: Ischemic Stroke. Vol. 92. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 2003: 281–291.
  27. Grotemeyer K. et al. Two-year follow-up of aspirin responder and aspirin nоn responder. A pilot-study including 180 post-stroke patients.Thromb. Res. 1993; 71: 397–403.
  28. Guyatt G.H., Akl E.A., Crowther M. et al. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): 7S–47S.
  29. Halushka M. et al. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin. Pharmacol. Ther. 2003; 73: 122–130.
  30. Hankey G.J., Eikelboom J.W. Aspirin resistance. The Lancet 2006; 367 (9510): 606–617.
  31. Jauch E.C., Saver J.L., Adams H.P. et al. American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association. American Stroke Association. Stroke 2013; 44 (3): 870–947.
  32. Karepov V., Tolpina G., Kuliczkowski W., Serebruany V Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. Cerebrovasc Dis. 2008; 26 (3): 272–276.
  33. Krasopoulos G. et al. Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336 (7637): 195–198.
  34. Lordkipanidze M., Diodati J.G., Palisaitis D.A. et al. Genetic determinants of response to aspirin: appraisal of 4 candidate genes. Thromb Res. 2011; 128: 47–53.
  35. Lordkipanidzé M. Advances in monitoring of aspirin therapy. Platelets 2012; 23 (7): 526–536 (адаптировано).
  36. Macchi L., Sorel N., Christiaens L. Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. Curr Pharm Des. 2006; 12 (2): 251–258.
  37. Meschia J.F., Bushnell C., Boden-Albala B. et al. American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association. American Stroke Association.Stroke. 2014 Dec; 45 (12): 3754–3832.
  38. Michelson A. et al. Resistance to antiplatelet drugs. Eur. Heart. J. 2006; 8(suppl. G): 53–58.
  39. Michelson A.D. et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J. Thromb. Haemost. 2005; 3: 1309–1311.
  40. Patrono С., Garcıa Rodrıguez L.A., Landolfi R., Baigent C. Low-dose aspirin for the prevention of atherothrombosis. The New England Journal of Medicine 2005; 353; 22: 2373–2383.
  41. Paul R., Banerjee A.K., Guha S. et al. Study of platelet aggregation in acute coronary syndrome with special reference to metabolic syndrome. Int J Appl Basic Med Res. 2013; 3 (2): 117–121.
  42. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231 (25): 232–235.
  43. Weisman S.M., Rabe C.S. Aspirin: new tricks for an old drug. Primary Care Reports 1998; 4: 239–246.
  44. Weng Z., Li X., Li Y. et al. The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. PLoS One 2013; 8: e78093.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Tanashyan M.M., Domashenko M.A., Raskurazhev A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-83204 от 12.05.2022.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies